Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Abstract Th0038: Endothelial CD40 Drives EndMT-Induced Inflammation In Atherosclerosis
Dzobo, Kim E. , Shami, Annelie , Nardi, Valentina , Xiong, Yuning, Edsfeldt, Andreas , Lutgens, Esther, Nardi, Valentina , Nardi, Valentina , Nitz, Katrin , Sun, Jiangming , Gialeli, Chrysostomi , Barghouth, Mohammad , Lerman, Amir , Wang, Ying , Gonçalves, Isabel , Simons, Michael , Lutgens, Esther

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | June 23, 2025 | Volume: 45 | Issue: Suppl_1 | Pages: No page available

10.1161/atv.45.suppl_1.th0038 Get It

Introduction: Atherosclerosis, the underlying cause of cardiovascular disease (CVD), is a lipid-driven chronic inflammatory disease. We have identified the co-stimulatory CD40-CD40L immune checkpoint dyad as a key driver of inflammation during atherosclerosis. CD40 and CD40L exert cell-type divergent functions via different signaling pathways. Hypothesis: We hypothesize that CD40 on endothelial cell (ECs) induces endothelial-to-mesenchymal transition (EndMT)-mediated vascular inflammation in atherosclerosis. Methods & Results: Using single cell RNAseq, we found that CD40 (TNFRSF5) is expressed on PDE3A + GJA5 + and KDR + COL15A1 + ECs of advanced human carotid atherosclerotic plaques. CD40 is highly expressed in the endothelial lining of human and mouse atherosclerotic plaques, and colocalizes with the EndMT markers fibronectin and collagen and adhesion molecule ICAM-1. CD40L activation of human aortic endothelial cells (HAECs) results in expression of the EndMT markers fibronectin, vimentin, sm22α, FSP1 and snail. Activation of CD40 in EC induces filamin A dependent translocation of CD40 into lipid rafts, increases TNF-receptor associated factor (TRAFs) -2, -3 and 6 levels, induces Akt signaling and increases expression of VCAM1 and CCL2. Conclusions: The endothelial cell has been more and more regarded as a cell type that plays a major role in driving inflammation. Our data suggest that the CD40-CD40L axis plays a significant role in EC-mediated inflammation in atherosclerosis by driving EndMT.
Microwave Ablation Versus Surgical Resection for Small (≤3 cm) Hepatocellular Carcinoma in Older Patients: A Propensity Score Matching Analysis
Chen, K H , Ji, Yimin , Wang, Gongzheng , Chen, Wen , Zhu, Qiang , Wang, Ximing , Liu, Cuihong , Zhao, Xinya , Chen, Kaige , Chen, Wen , Liu, Cuihong

Mayo Clinic

Korean Journal of Radiology | June 23, 2025 | Volume: 26 | Issue: 7 | Pages: 650

10.3348/kjr.2025.0049 | PMID 40590077 Get It

Downregulation of LATS1/2 Drives Endothelial Senescence-Associated Stemness (SAS) and Atherothrombotic Lesion Formation
Kotla, Sivareddy , Ko, Kyung Ae , Chen, Weiqing , Samanthapudi, Venkata Subrahman K, Hoang, O.N. , Mejia, Gilbert, Li, Shengyu , Schadler, Keri , Rivera, Luis Antonio, Samperio, Kay Carlene Tavares, Kim, Jung Hyun , Mendoza, Keila Carolina Ostos , Mariscal-Reyes, Karla N., Fujiwara, Keigi , Gi, Young Jin , Pathania, Rajneesh , Morrell, C Jane, Lorenzi, Philip L. , Tan, Lin , Chini, Eduardo N. , Herrmann, Joerg, Vasquez, Hernan G., Shen, Ying H. , Martin, James F. , Le, Nhat‐Tu , Kim, Jung Hyun , Lee, Jonghae , Chen, Weiqing , Hoang, Oanh , Mejia, Gilbert , Schadler, Keri , Ostos-Mendoza, Keila C , Deswal, Anita M , Cooke, John P , Fujiwara, Keigi , Palaskas, Nicolas L , Koutroumpakis, Efstratios , Lorenzi, Philip L , Madhmud, Iqbal , Hanssen, Nordin M J , Shen, Ying H , Martin, James F , Seeley, Erin , Burks, Jared K , Brookes, Paul S , Wang, Guangyu , Le, Nhat-Tu , Abe, Jun-Ichi , Kotla, Sivareddy , Kim, Jung Hyun , Lee, Jonghae , Rivera, Luis Antonio, Imanishi, Masaki , Cooke, John P. , Morrell, Criag, Yvan-Charvet, Laurent , Herrmann, Joerg, Xu, Haodong , Wang, Guangyu

Mayo Clinic

No container title available | June 22, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.06.19.660635 | PMID 40667385 Get It

ABSTRACT Background Atherothrombosis, the main event leading to acute coronary syndrome (ACS), is strongly linked to disturbed blood flow (d-flow) regions. Although the involvement of the Hippo pathway and its kinases Large Tumor Suppressor Kinase 1and 2 (LATS 1 and 2) in mechanical stress responses is known, the mechanisms by which d-flow simultaneously induces senescence, proliferation, and atherothrombosis remain unclear. Methods The role of endothelial cells (EC)-specific LATS1/2 was examined using EC specific knock-out (EKO) mice in a partial left carotid ligation (PLCL) model. Plaque spatial multi-omics analysis was performed by integrating imaging mass cytometry, sequential immunofluorescence (COMET™), and spatial metabolomics at the single-cell level in human and mouse atherosclerotic plaques. Results In tamoxifen-inducible Lats1 homo( -/- ) / Lats2 homo( -/- ) EC-specific knockout (EKO) mice, deletion of LATS1/2 induced by tamoxifen led to fatal outcomes, characterized by severe systemic edema and markedly increased vascular permeability. In contrast, Lats1 het(+ /- ) / Lats2 homo( -/- ) -EKO mice survived and developed atherothrombotic plaques exhibiting neovascularization even without further additional dietary or genetic intervention. Spatial proteomics analysis revealed that LATS1/2 depletion in ECs triggered a senescence-associated stemness (SAS) phenotype, primarily driven by CD38 upregulation. Complementary spatial metabolomics profiling demonstrated a significant increase in sulfite and taurine within LATS1/2-deficient plaques, indicating lowered sulfite oxidase (SUOX) activity. Mechanistically, CD38 upregulation was found to suppress SUOX expression, induce the reverse mode of mitochondrial complex V, and increase succinate dehydrogenase (SDH) activity along with ATP consumption. Paradoxically, despite ATP depletion, this metabolic disturbance enhanced glutamate metabolism and the tricarboxylic acid (TCA) cycle, sustaining EC proliferation under energetically stressed conditions. The combined effect of LATS1/2 deletion and CD38 activation established a unique EC phenotype defined by increased SAS, leading to proliferation, senescence, and eventual cell death. These pathological processes culminated in the formation of atherothrombotic plaques, which were attenuated by inhibition of CD38. Notably, a similar phenotype—marked by metabolically active ECs—was observed in human atherothrombotic plaques, suggesting translational relevance. Conclusion Loss of LATS1/2 in ECs induces SAS state that promotes excessive EC proliferation, senescent cell accumulation, and the development of structurally fragile, leaky neo vessels—hallmarks of atherothrombotic lesions. CD38-mediated SUOX deficiency further amplifies this pathological process by inducing mitochondrial dysfunction, depleting ATP, and triggering compensatory upregulation of glutamate and TCA cycle metabolism. These findings identify a novel LATS1/2–CD38–SUOX axis in ECs that orchestrates SAS-driven atherothrombosis. Targeting CD38 may represent a promising therapeutic strategy to mitigate vascular dysfunction and plaque instability in high-risk ACS patients. Graphical abstract Under normal physiological conditions, LATS1/2 and Lamin A work together to suppress CD38 expression. Lamin A binds directly to the CD38 promoter to repress transcription, and LATS1/2 interact with Lamin A to reinforce this suppression. This collaboration helps maintain low CD38 activity and preserves cellular NAD⁺ levels. However, under disturbed flow (d-flow), both LATS1/2 and Lamin A are downregulated. The loss of this dual repression leads to increased CD38 NADase expression. Elevated CD38 accelerates NAD⁺ consumption, causing NAD⁺ depletion—a hallmark of cellular senescence. Reduced NAD⁺ disrupts key metabolic and stress-response pathways, contributing to the onset of the senescent state. At the same time, CD38 suppresses sulfite oxidase (SUOX), leading to sulfite accumulation and mitochondrial redox imbalance. This shift activates the reverse mode of mitochondrial Complex V, which decreases ATP production and increases mitochondrial ROS, intensifying metabolic and oxidative stress in endothelial cells (ECs). In response, ECs compensate by upregulating succinate dehydrogenase (SDH), enhancing TCA cycle activity and glutamate metabolism. This metabolic adaptation provides the biosynthetic building blocks needed for cell growth and proliferation. As a result, ECs adopt a paradoxical phenotype: they show classical features of stress-induced senescence (such as NAD⁺ depletion, oxidative stress, and cell cycle arrest signals), while simultaneously undergoing metabolic activation and proliferation, also mediated by YAP. This defines a non-canonical endothelial program known as senescence-associated stemness (SAS), characterized by the formation of abnormal, proliferative, yet fragile neovessels. These dysfunctional vessels contribute to atherothrombosis, setting this process apart from the more stable lesions typical of conventional atherosclerosis.
Sacral fracture risk after stereotactic spinal radiosurgery: a multi-institution, retrospective analysis
Goethe, Eric A. , Almeida, Romulo Augusto Andrade de, Mikula, Anthony L. , Merrell, Kenneth W. , Rose, Peter S. , Karim, S. Mohammed, Linzey, Joseph R. , Szerlip, Nicholas J. , Ghia, Amol J. , Li, Jing , McAleer, Mary Frances, Perni, Subha , Yeboa, D.N. , Rhines, Laurence D. , North, Robert Y. , Almeida, Rômulo Augusto Andrade de , Call-Orellana, Francisco Alfredo , Clarke, Michelle J. , Amini, Behrang , Beckham, Thomas Hendrix , Tom, Martin C. , McAleer, Mary Frances , Wang, Chenyang , Price, Anthony, Alvarez‐Breckenridge, Christopher , Tatsui, Claudio Esteves

Mayo Clinic

Journal of Neurosurgery: Spine | June 20, 2025 | Volume: 43 | Issue: 3 | Pages: 305-312

10.3171/2025.2.spine24770 | PMID 40540799 Get It

OBJECTIVE Spinal stereotactic radiosurgery (SSRS) is an established treatment modality for spinal metastatic disease. A common complication of SSRS is postradiation pathologic fracture. The authors evaluated the risk of pathologic fracture in sacral SSRS. METHODS All patients receiving SSRS in 1 to 5 fractions to 1 or more sacral levels between 2011 and 2020 at participating institutions were included. Demographic, histological, anatomical, and outcome data were obtained from electronic medical records. Data were analyzed using SPSS version 28. RESULTS Of 67 total patients, 50 (74.6%) were men and 17 (25.4%) were women. The most common tumor histologies were prostate adenocarcinoma (n = 16 [23.9%]) and renal cell carcinoma (n = 12 [17.9%]). Median (range) age at treatment was 63 (8–87) years. The mean ± SD (range) number of levels treated was 1.5 ± 0.7 (1–4) levels. Mean ± SD (range) bone density at S1 was 208.0 ± 74.4 (−3.0 to 443.3) Hounsfield units (HUs). Median (range) follow-up was 16.6 (1.5–132) months, median ± SD (range) overall survival was 24 ± 21.0 (1.7–83.3) months, and the 1-year local control rate was 83.6%. Fourteen patients (20.9%) experienced fracture within the radiation field. There was no association between fracture and patient sex (p = 0.32), age (p = 0.40), S1 HU (p = 0.28), tumor location according to Denis classification (p = 0.87), presence of pain (p = 0.66), single versus multifraction radiation (p = 0.44), or number of levels treated (p = 0.52). Patients experiencing in-field progression were more likely to experience fracture (61.5% vs 10.2%, p < 0.001), and patients experiencing fracture had a higher average Spine Instability Neoplastic Score than patients without fracture (5.7 vs 4.3, p = 0.049). Only local control remained as a factor associated with sacral fracture in the multivariate analysis. Of the patients experiencing fracture, 10 (71.4%) were symptomatic and 3 of those (30.0%) underwent post-SSRS surgical intervention. CONCLUSIONS Pathologic fracture may occur after sacral SSRS in a significant number of patients and is significantly associated with failure of local control.
Transforming Biobanking with AI: Perspectives from Leading Experts
Abdelhafiz, Ahmed Samir , Henderson, Marianne K. , Kozlakidis, Zisis , Mahajan, Gouri , Wang, Weiye Charles , Grossman, Gregory , Ogishima, Soichi , Banerjee, Imon , Quinlan, Philip

Mayo Clinic

Biopreservation and Biobanking | June 20, 2025 | Volume: 24 | Issue: 3 | Pages: 209-215

10.1089/bio.2025.0101 | PMID 40538343 Get It

Label‐Free Single‐Molecule Immunoassay
Chen, Chao , Zhou, Shuang , Chemerkouh, Mohammad Javad Haji Najafi , Snozek, Christine L.H. , Jiang, Jiapei, Braswell, Brandyn, Chen, C.-H. , Wang, Shaopeng , Chen, Chao , Zhou, Xiaoyan , Ma, Guangzhong , Yang, Eric H. , Wan, Zijian , Zhou, Xinyu , Wang, Shaopeng

Mayo Clinic

Advanced Science | June 20, 2025 | Volume: 12 | Issue: 31 | Pages: No page available

10.1002/advs.202505207 | PMID 40538199 Get It

Abstract Single‐molecule immunoassay is a reliable technique for the detection and quantification of low‐abundance blood biomarkers, which are essential for early disease diagnosis and biomedical research. However, current single‐molecule methods predominantly rely on endpoint detection and necessitate signal amplification via labeling, which brings a variety of unwanted effects, like matrix effect and autofluorescence interference. This study introduces a real‐time mass imaging‐based label‐free single‐molecule immunoassay (LFSMiA). Featuring plasmonic scattering microscopy‐based mass imaging, a 2‐step sandwich assay format enables background reduction, minimization of matrix effect by dynamic tracking of single binding events, and fully leveraging real‐time data for improved measurement precision through a Bayesian Gaussian process model, the LFSMiA enables ultra‐sensitive and direct protein detection at the single‐molecule level in neat blood sample matrices. LFSMiA measurement is demonstrated for interleukin‐6 and prostate‐specific antigen in buffer, undiluted serum, and whole blood with sub‐femtomolar detection limits and eight logs of dynamic ranges. Moreover, comparable performance is achieved with an inexpensive miniaturized setup. To show its translational potential to clinical settings and point‐of‐care diagnostics, N‐terminal pro‐B‐type natriuretic peptide is examined in patient whole blood samples using the LFSMiA and results in a strong linear correlation (r > 0.99) with standard clinical lab results.
Impact of SGLT2i on Cardiovascular Outcomes Following Acute Myocardial Infarction With Heart Failure With Preserved Ejection Fraction: Propensity-matched Registry Study
Calcagno, Tess , Issa, Rochell , Canova, Tyler , Issa, Ryan, Menon, Venu , Griffin, Brian P. , Kwon, Deborah , Wang, Tom Kai Ming , Wang, Tom Kai Ming , Kaelber, David C. , Tang, Weihong

Mayo Clinic

Angiology | June 19, 2025 | Volume: 77 | Issue: 7 | Pages: 875-882

10.1177/00033197251345853 | PMID 40534435 Get It

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have demonstrated benefits in heart failure with preserved ejection fraction (HFpEF), but their impact following acute myocardial infarction (AMI) is less well understood. Using the TriNetX Research Network (TriNetX) multi-center registry (2014–2022), we identified patients with heart failure with preserved ejection fraction (HFpEF)—defined as left ventricular ejection fraction (LVEF) >50% and New York Heart Association (NYHA) class II–IV—not previously treated with sodium-glucose co-transporter 2 inhibitors (SGLT2i) who experienced an acute myocardial infarction (AMI). Patients who initiated SGLT2i within 1-year post-AMI were compared with those who did not. Propensity score matching was used to balance cohorts ( n = 20,423 each; mean age 68.3 ± 11.0 years; 54.5% female) for demographics, comorbidities, and treatment variables. The primary outcome was a composite of major adverse cardiovascular events (MACE), including all-cause mortality, recurrent AMI, acute heart failure, and stroke. Secondary outcomes included cardiac arrest and major bleeding. SGLT2i use was associated with lower rates of MACE (3.7% vs 6.1%; P = .0005), all-cause mortality (0.9% vs 5.6%; P < .0001), and other adverse events at both 30 days and 1 year. In this large, propensity-matched cohort, SGLT2i use post-AMI in HFpEF patients was associated with favorable cardiovascular outcomes. Further studies are needed to confirm these associations.
Transcranial Electrical Stimulation in Treatment of Depression
Ren, Caili , Wang, Zhen , Kung, Simon , Boyapati, Renu Bhargavi, Islam, Karimul , Li, John Wing , Shelton, K. Maureen, Waniger, Anne , Rydberg, Ann , Pascual–Leone, A., Pagali, Sandeep R. , Li, John W, Rydberg, Ann M, Boyapati, Renu Bhargavi, Islam, Karimul, Hassett, Leslie C. , Croarkin, Paul E. , Lundstrom, Brian N. , Lapid, Maria I.

Mayo Clinic

JAMA Network Open | June 18, 2025 | Volume: 8 | Issue: 6 | Pages: e2516459

10.1001/jamanetworkopen.2025.16459 | PMID 40531534 Get It

Importance The role and safety of transcranial electrical stimulation (tES) for treating depressive disorders remain under evaluation. Objective To evaluate tES treatment in patients with major depressive disorder (MDD) and comorbid depressive conditions. Data Sources A search of MEDLINE, Embase, Cochrane, APA PsycINFO, and Scopus databases was conducted from inception to September 17, 2024. Study Selection Randomized clinical trials (RCTs) of adults with MDD, depression with psychiatric comorbidities (DPC), or depression with medical comorbidities (DMC), treated with transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), or transcranial random noise stimulation (tRNS), compared with sham or other treatments were included. Data Extraction and Synthesis Independent reviewers extracted data in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, with random-effects meta-analysis used for pooling. Main Outcomes and Measures Primary outcomes were depression severity, response and remission rates, and adverse events. Standardized mean differences (SMDs) were reported for continuous outcomes, and odds ratios (ORs) were reported for categorical outcomes. Quality of evidence (QOE) was assessed using the Grading of Recommendations Assessment, Development, and Evaluation criteria. Results The meta-analysis included 5522 participants from 114 study groups from 88 RCTs (3198 female [58.9%]; mean [range] age, 43.1 [19.4-76.9] years). Most studies (104 study groups from 79 RCTs [91.2%]) evaluated tDCS, while 7 study groups from 6 RCTs (6.1%) evaluated tACS, and 3 study groups from 3 RCTs (2.7%) evaluated tRNS. tES was associated with reduced depressive symptoms (SMD = −0.59; 95% CI, −0.83 to −0.35; low QOE) and improvement in DMC (SMD = −1.05; 95% CI, −1.67 to −0.43; low QOE) and DPC (SMD = −0.78; 95% CI, −1.27 to −0.29; low QOE) compared with MDD (SMD = −0.22; 95% CI, −0.44 to 0.01; low QOE). tDCS was associated with reduced depression in DMC (SMD = −1.05; 95% CI, −1.70 to −0.40; very low QOE) and DPC (SMD = −0.88; 95% CI, −1.40 to −0.36; low QOE) but not MDD. tACS was associated with improved MDD symptoms (SMD = −0.58; 95% CI, −0.96 to −0.20; high QOE) and response rates (OR, 2.07; 95% CI, 1.34 to 3.19; high QOE). Combined tDCS and medication was associated with reduced symptoms (SMD = −0.51; 95% CI, −0.90 to −0.13; moderate QOE) and increased response (OR, 2.25; 95% CI, 1.08 to 4.65; high QOE) in MDD. tDCS combined with psychotherapy was not associated with improvement. Subgroup analysis showed that anodal left dorsolateral prefrontal cortex DCS was associated with improved outcomes. Mild to moderate adverse events were more frequent in tES groups. Conclusions and Relevance In this systematic review and meta-analysis, tDCS was associated with improvement in depression among patients with DMC and DPC (with smaller benefits in MDD), tACS was associated with improved MDD outcomes (while tRNS had insufficient evidence) in smaller samples, and combined tDCS and medication was associated with improvement in depression. These findings suggest that tES is well-tolerated overall, with only mild to moderate adverse events, and that future research should optimize stimulation parameters and individualize tES interventions.
Cardiac Computed Tomography for Prosthetic Heart Valve Assessment. An Expert Consensus Document of the Society of Cardiovascular Computed Tomography (SCCT), the American College of Cardiology (ACC), the European Soci
Budde, Ricardo P.J. , Faure, M. , Cremer, Paul , Feuchtner, Gudrun , Gonzales, Holly M, Kiefer, Todd L., Leipsic, Jonathon , Nieman, Koen , Williamson, Eric E. , Ballmoos, Moritz C. Wyler von , Salgado, Rodrigo , Faure, Marguerite E , Abbara, Suhny , Alkadhi, Hatem , Cremer, Paul C , Feuchtner, Gudrun M , Gonzales, Holly M , Leipsic, Jonathan , Nieman, Koen , Revels, Jonathan W , Wang, Dee Dee , Williamson, Eric , Salgado, Rodrigo , Budde, Ricardo Peter Jurgen , Revels, Jonathan , Wang, Dee Dee , Zwischenberger, Brittany A.

Mayo Clinic

Radiology: Cardiothoracic Imaging | June 17, 2025 | Volume: 7 | Issue: 3 | Pages: No page available

10.1148/ryct.250231 | PMID 40526484 Get It

Prosthetic heart valve (PHV) dysfunction is increasingly seen due to the increase in the number of PHV that are being implanted worldwide. Cardiac CT imaging has emerged as a valuable tool to assess PHVs and determine the cause of dysfunction. This consensus document first summarizes the available techniques for PHV assessment. Then the use of CT in PHV (dys)function assessment is discussed in detail including consensus statements for correct indications and patient selection for CT assessment of PHVs, image acquisition, reconstruction and measurement protocols and how to interpret and report the CT findings for specific types of PHV dysfunction. This article was published in Journal of Cardiovascular Computed Tomography, Budde RPJ et al, Cardiac computed tomography for prosthetic heart valve assessment: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT), the American College of Cardiology (ACC), the European Society of Cardiovascular Radiology (ESCR), the North American Society for Cardiovascular Imaging (NASCI), the Radiological Society of North America (RSNA), the Society for Cardiovascular Angiography & Interventions (SCAI), and the Society of Thoracic Surgeons (STS). The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation may be used when referencing this document. © 2025 Society of Cardiovascular Computed Tomography. Published by Elsevier Inc. on behalf of the Society of Cardiovascular Computed Tomography. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). Keywords: Computed Tomography, Valve, Cardiac, Imaging, Dysfunction, Prosthetic
Impact of granulocyte colony‐stimulating factor on safety of chimeric antigen receptor‐T‐cell therapy in non‐Hodgkin lymphoma
Chung, Kevin , Ng, Lay She , Bansal, Radhika , Kharfan‐Dabaja, Mohamed A. , Nowakowski, Grzegorz S. , Castro, Januario E. , Ng, Wern Lynn , Lin, Yi , Yee, Claire I., Kharfan-Dabaja, Mohamed A , Rosenthal, Allison C, Castro, Januario, Murthy, Hemant S , Iqbal, Madiha , Wang, Yucai , Hilal, Talal , Castro, Januario E , Yee, Claire , Rosenthal, Allison , Muñoz, Javier , Murthy, Hemant S. , Iqbal, Madiha , Wang, Yucai , Hilal, Talal

Mayo Clinic

British Journal of Haematology | June 17, 2025 | Volume: 207 | Issue: 2 | Pages: 606-611

10.1111/bjh.20207 | PMID 40524548 Get It